Authorship: In addition to Jain, Mass General Brigham authors include Lance L. Munn. Additional authors include Andreas G. Hadjigeorgiou, Constantinos Harkos, and Triantafyllos Stylianopoulos of the University of Cyprus and Aditya K. Mishra, Golnaz Morad, Sarah B. Johnson, Nadim J. Ajami, and Jennifer A. Wargo from the University of Texas MD Anderson Medical Center.
Paper cited: Hadjigeorgiou, AG., et al. “Mathematical Modeling and Association Analysis Deciphers the Impact of the Gut Microbiome on Cancer Immunotherapy.” Cancer Research. DOI: 10.1158/0008-5472.CAN-24-2232
Funding: This work was supported by grants from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (863955, 101141357), NIH grants R01CA247441, R21EB031982 and U01CA2618425, R01-CA259253, R01-CA208205, R01-NS118929, R01CA219896, U01-CA261842, and U01-CA 224348, Outstanding Investigator Award (R35-CA197743), F32CA260769, and the National Foundation for Cancer Research, Jane’s Trust Foundation, Niles Albright Research Foundation and Harvard Ludwig Cancer Center.
Disclosures: Jain received consultant fees from Cur, DynamiCure, Elpis, Innocoll, Merck, SynDevRx; owns equity in Accurius, Enlight, SynDevRx; and served on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund; and received grants from Boehringer Ingelheim and Sanofi. Jennifer A. Wargo is an inventor of US patent applications WO2020150429A1, US20200129569A1, WO2019191390A2, WO2020106983A1; reports advisory roles and honoraria Daiichi Sankyo, Gustave Roussy Cancer Center, EverImmune, and OSE Immunotherapeutics.Wargo receives stock options from Micronoma. Munn receives equity from Bayer and is a consultant for SimBiosys. Neither any reagent nor any funding from any of the above organizations was used in this study. Other co-authors have no conflict of interest to declare.
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.